Bronitin Mist
(Norepinephrine Bitartrate)ApprovedSmall molecule
Bronitin Mist is one of 39 small molecule programs targeting Sepsis. It is currently in Approved.
2
Indications
4
Total Trials
2
Active Trials
38
Competitors
7
FDA Applications
NDA/BLA/ANDA regulatory filings
13
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
112 competitors in Sepsis
#DrugCompanyPhaseTrials
1Bronitin Mist
LLongeveron Inc.
Approved
Olumiant
Eli LillyPhase 2
N-Acetylcysteine (NAC) Treatment
TThe First Affiliated Hospital of Soochow University
Phase 3
Decadron
AAspen Global Incorporated
Phase 2
Heparin Sodium
BBaxter Healthcare Corporation
Phase 2
Nafamostat Mesylate
EEnsysce Biosciences
Phase 3
Hydrocortisone Administration
UUniversity of Virginia
Phase 3
AZD4144
AstraZenecaPhase 2
Simdax
Orion Corporation, Orion PharmaPreclinical
Zyvox
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
LEVOPHED
NDA NDA007513
Jan 1, 1982
BRONITIN MIST
NDA NDA016126
Jan 1, 1982
MEDIHALER-EPI
NDA NDA010374
Sep 15, 2022
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
NDA NDA215700
Oct 6, 2022
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
NDA NDA214628
Feb 28, 2025
EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
NDA NDA218475
Feb 6, 2026
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
NDA NDA214313
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Norepinephrine Bitartrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- LLongeveron Inc.